Member Info for Steveo_76

I also got a response from Phil as per the below:

Thank you for your email. We have passed your feedback onto the Company.

As well as the Proactive interview you mentioned, Mo also appeared on Vox Markets to discuss the news. The Company has also highlighted the contract through its social media channels and will continue to leverage the news with potential clients.

In terms of revenue guidance for 2026, the Company provided its expected revenue performance for the year, which as is typical, is not limited to signed contracts.

As the LOI for the ILiAD study was signed in January 2025, the Company expected revenues from a resulting contract to be realised during 2026 and therefore reflected this within its guidance. This was not included in the £30m orderbook figure reported at results, which has subsequently been significantly bolstered through the ILiAD and Traws Pharma contracts.

We are not able to provide further detail of the specific contribution of the ILiAD contract to 2026 revenue guidance, as the financial details around the contract are commercially sensitive.

At the FY 2025 results, hVIVO reiterated its expectation of high single-digit revenue growth for 2026, weighted to H2. As always, should there be any materially change to expected performance, the Company will update the market accordingly. A half year trading update is expected around July, consistent with prior years.

I'm in the same boat Rusty. I first invested in this in 2021 and have an average in the 20s so I'm well underwater. I think it's worth contacting IR about this to see if we can gain more clarity and highlight that there are concerns. It's really upsetting and frustrating that what should be huge groundbreaking news for the company that we've all been waiting ages for has seen the share price drop by circa 10% from Tuesdays close . This should have been a return to double figures and the beginning of the climb back up but the release of the information hasn't been handled very well.

If you watch the results presentation he actually says revenue from Iliad would be recognised in 2026 and 2027 with the majority being in 2027. So what he said yesterday was naive because it allows people to jump to the assumption it will all be in 2026 and then scaremonger that there basically won't be any other HCT business.

I think it's important to be clear what Mo has said about the revenue recognition of the Iliad contract. I've gone back and listened to the final results presentation and in that guidance he says that the Iliad revenue would be recognised in 2026 and 2027 but more in 2027. In today's interview he says again that he expects to recognise most of the revenue in 26 & 27. The key here is didn't specify that it would be more in 27 like he did in the results presentation but he made quite a big point in that of the fact that due to the delays with Iliad that most of it would be 27. So I think that Iliad being included in 26 guidance would be a smaller part of the overall contract value and hence not form a large part of the overall guidance.

Sentiment firmly against this at the moment, I'm sure it will turn but a lot of damage has been done. As for Mo treating shareholders with contempt this means he is treating himself with contempt as he has bought shares on 2 occasions now..... I'm sure he is as annoyed and frustrated as anyone by this, that's not to say that he could/should do better with his comms.

Looks like ILiAD is progressing into Phase 3 with it's Whooping Cough vaccine:

https://www.uhs.nhs.uk/whats-new/press-releases/new-vaccine-offers-fresh-hope-for-controlling-whooping-cough

Good to see some more engagement on this board as it's been dead for a while now. I am massively underwater here, been holding and adding since Jan 2021 - still believe in the company and what it is doing, it has broadly been victim of a wider bio/pharma malaise which can't last for ever.

Nathan, particularly appreciated your post as I've been reading this board for years and always found your contributions really useful given that I believe you have a background in the sector and seem very informed. Hope you can ignore some of the barbs from other posters and keep posting from time to time to provide us with information. Overall though most of us whatever our views are behind the common cause of wishing Hvivo well so important to remember that even when we may disagree on things.

Title of Andrew Catchpole's presentation on 5th April at 17.10 now showing on the WVC Washington website:
Challenge studies – can the results be expected to mimic field trial data?

Great post by Jigger on Twitter worth checking out re DIM: https://twitter.com/Jigger93609885/status/1627321281631625216

Exciting times for Hvivo, the core business is in great health and feel like we will hear some news re one of the spinouts soon.

Seeing as this has not been under 8p since 2020 I don't think I agree with your comment. This has been undervalued for a while and was overdue a correction hopefully a bit of a dip here and then continue the journey back towards 20p+

Back to where we were before the £13 million contract news. Unbelievable really when such a large contract has absolutely no effect particularly when share price is undervalued anyway.

Pleased for Poolbeg and seems like good validation for DIM. When are we going to get an RNS here though, seems like an eternity since the last contract. Surely a couple to come before the Xmas break.

For me this is a classic case of spreading rumours and talking down a share to cause panic and drive the price down only to buy and sell it as it rises back. They will not be getting my shares.

Stt1,

I know from reading ADVFN that you like to pump TLY that's fair enough. In all honesty I don't know much about the company but seems like it has carved out a decent niche providing an ever more stretched NHS with provisions as it tries to catch up with the Covid backlog. I've just checked current performance of TLY on MarketWatch and it is at the same level as this time last year which given market conditions is a decent effort but not quite the picture you paint.

Going back to my original comment, I track a number of other healthcare/biotech related stocks: DDDD, SNG, Genedrive, NCYT, SBTX, ODX and they have all seen big drop offs from highs. So the point I was making is that it isn't just ORPH and you can't completely park at CFs door as some have. Admittedly his over promising certainly hasn't helped but it is only part of the reason for the drop. Personally I will continue to hold as I feel the core business is solid shape in and that Human Challenge Studies are going to be increasingly sought after in the vaccine space. Hopefully the spin outs will appear at some point but I'm not going to speculate as to there worth, we'll have to wait and see.

More negativity than ever here, I could understand it more if it were constructive and based on thorough research but often it is just lazily recycling the same old lines around 'CFs blarney'. Certainly makes me think that a number of these posters are being disingenuous! Share price aside I am still broadly happy with the progress of the core business, the spin outs have been a disappointment of course though I wonder what state the SPs would be on those if the had all been spun out - no doubt smashed down with the rest of the market. The AIM health/biotech sector has been suffering for a good while now and predates Russia invading Ukraine, I think you'd struggle to find an AIM health/biotech that has performed well since the end of summer 2021.

Very solid set of results and exciting forward guidance. Well done to Mo, CF and the team!

Moni, always used to find your previous input on the Orph board useful and we had a couple of exchanges about Polb a few months back now when you were negative but constructive. Now it just feels like you are purposefully being very negative and deramping. Perhaps you are hoping for a sharp drop and will then stock up? A shame and hope you return back to being more constructive with your posting soon.

Great to see the peer study review validating the human challenge model. Green light for Orph to move forwards now and unique position as the only company able to provide Covid-19 human challenge studies. Coupled with other news and developments in the pipeline and expected revenue beat, I am very excited for the months ahead.

Covid far from done yet: https://medriva.com/china-at-a-covid-tipping-point/

I expect to see some Covid CHIMS announced in the not too distant future and this work should continue for some time to come. Orph will be able to charge a good premium.

We already own 62.6% of Prep, it's Imutex we own 49% of. I couldn't see him buying the rest of Imutex, it would take too much investment to then get it through phase 3.